State and School Employees' Health Insurance Plan - Rituximab Non-Oncology
Summary
Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), and Truxima (rituximab-abbs) may be considered medically necessary for listed non-oncologic indications when the criteria for that condition are met, including rheumatoid arthritis, ANCA-associated vasculitis, pemphigus, autoimmune hemolytic anemia, chronic graft versus host disease, immune thrombocytopenia, neuromyelitis optica spectrum disorder, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, multiple sclerosis, membranous nephropathy, and refractory myasthenia gravis. The 11/01/2026 update added Riabni as medically necessary and added HCPCS code Q5123. The 06/15/2026 update revised the criteria for the listed conditions and added a prescriber and dosage requirement.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.